What's going on with the CSL share price on Tuesday?

The ASX biotech giant is moving along with its Vifor takeover…

| More on:
Happy healthcare workers in a labs

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • CSL shares push dip into the red in early trade in line with a fall across the ASX 200 index 
  • The company announced that it has met all regulatory approvals for the Vifor acquisition which will be finalised by 9 August (next Tuesday)
  • CSL also appointed Hervé Gisserot as the general manager of Vifor once the takeover is complete

The CSL Ltd (ASX: CSL) share price is edging lower in early trading amid the company's latest update on its Vifor acquisition.

At the time of writing, shares in the global biotech are down slightly by 0.27% to $294.10.

Meantime, the S&P/ASX 200 Index (ASX: XJO) is also hovering 0.36% lower to 6,967.6 points.

What did CSL announce to the ASX?

In its announcement, CSL advised it has received all regulatory clearances to finalise the acquisition of Vifor Pharma, effective today.

This comes after the lengthy delay earlier this year regarding the foreign direct investment and regulatory filings.

Nonetheless, with all conditions now met, the takeover of the global specialty pharmaceuticals company will take place by 9 August.

CSL expects to hold more than 97% of Vifor shares upon completion and will seek to cancel the remaining 3%. This will be in accordance with Swiss takeover rules, with CSL also applying for the delisting of these shares on the Swiss Exchange (SIX).

CSL CEO and managing director Paul Perreault commented:

We are excited to complete the acquisition of Vifor Pharma — enhancing CSL's well-established patient focus and ability to protect the health of those facing a range of rare and serious medical conditions.

Perreault went on to add:

Joining CSL, the Vifor business adds near-term value along with a clear path to long-term sustainable growth. It also adds an outstanding management team, along with a high-value and complementary portfolio of products and market leading position in the nephrology and iron deficiency spaces.

Investors may want to keep an eye out on 17 October as CSL will hold a dedicated Vifor market briefing. Management will discuss Vifor's growth strategy and insights into its product portfolio and financials.

CSL appoints general manager for Vifor

In other news, CSL has appointed Hervé Gisserot as general manager for the Vifor business once the acquisition is finalised.

Reporting directly to Perreault, the appointment of Gisserot should be a smooth transition given his credentials and current position.

Since January 2022, Gisserot has been the chief commercial officer for Vifor Pharma.

Previously, he spent 13 years at GlaxoSmithKline fulfilling multiple senior vice president (SVP) titles. This includes the most recent, SVP & Head of Pharmaceuticals & Vaccines for Greater China & Intercontinental.

CSL share price snapshot

Despite the recent market volatility, the CSL share price has outperformed the market to surge almost 10% in a month.

For context, the benchmark ASX 200 index has lifted around 7% over the same time frame.

CSL is the third largest company on the ASX with a market capitalisation of roughly $142 billion.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Share Gainers

Why A2 Milk, EOS, GQG, and Mineral Resources shares are racing higher today

These shares are ending the week strongly. But why?

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why Megaport, Pilbara Minerals, Vysarn, and WiseTech shares are falling today

These shares are ending the week in the red. But why?

Read more »

Two smiling work colleagues discuss an investment or business plan at their office.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young female investor sits in her home office looking at her ipad and smiling as she sees the QBE share price rising
Share Market News

5 things to watch on the ASX 200 on Friday

A good finish to the week is expected for Aussie investors.

Read more »

A man has computer-generated images rushing through his head indicating an AI (Artificial Intelligence) concept of a communication network.
Technology Shares

ASX investors are obsessed with Nvidia shares! Here's why

The global chipmaker reported a 94% increase in annual revenue in the third quarter.

Read more »

A man wearing a red jacket and mountain hiking clothes stands at the top of a mountain peak and looks out over countless mountain ranges.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another disappointing day for ASX investors this Thursday.

Read more »

two racing cars battle to take first place on a formula one track with one tailing the the leader and looking to overtake the car.
Opinions

Down 21% in 2024. This ASX 300 stock looks like a money-making monster

Profits are expected to plunge, but the future could still be bright.

Read more »

A businesswoman exhales a deep sigh after receiving bad news, and gets on with it.
52-Week Lows

Down 68% from highs, this ASX 200 stock just hit a 4-year low. Time to pounce?

Is this beaten down stock a buy? Let's see what one leading broker is saying.

Read more »